AIM ImmunoTech develops therapies for cancers, viral diseases and immune disorders, led by its Ampligen treatment candidate. AIM reports earnings on Mon, Nov 16, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 20 | Ascendiant Capital | Target lowered | Buy | |
| Jun 1 | Ascendiant Capital | Maintained | Buy |
Seasonality
How AIM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in AIM in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AIM is in one of them and how their past AIM trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AIM in an article yet. Here's the latest on the wider market.
About AIM ImmunoTech
AIM ImmunoTech is a biopharmaceutical company based in Ocala, Florida, that develops treatments for cancers, viral diseases and immune disorders. Its lead candidate, Ampligen, is an RNA molecule being studied mainly for pancreatic cancer, with other studies covering viral infections and fatigue after COVID-19. Ampligen is approved for sale in Argentina for severe chronic fatigue syndrome but has not been approved in the United States. The company also offers Alferon N Injection, an interferon product, and aims its therapies at patients with conditions where treatment options are limited.
- Headquarters
- Ocala, FL